Author/Editor		Kovač, V; Zwitter, M; Smrdel, U; Debeljak, A; Cesar, R
Title		Low-dose gemcitabine in prolonged infusion and cisplatin for malignant pleural mesothelioma: a phase I - II trial
Type		članek
Source		In: Jassem J, editor. 9th central European lung cancer conference; 2004 Sep 23-25; Gdansk. Bologna: Medimond, Monduzzi editore, International proceedings division,
Publication year		2004
Volume		str. 131-4
Language		eng
Abstract		In a phase I-II trial, 23 patients (pts) with malignant pleural mesothelioma (MPM) were treated with low-dose gemcitabine in long infusion and cisplatin. Treatrneret: On days 1 and 8 of a 3-week cycle, the pts received gemcitabine in a 6-hour infusion in escalating doses from 130 mg/m2 to 250 mg/m2. On day 2, all pts received cisplatin at 75 mg/m2. Toxicity: Nausea and vomiting were common but manageable. Most pts had reversible thrombocytosis and alopecia. Leucopenia, neutropenia and thrombocytopenia were rare. Anaemia was common: grade 4/3 in 1 pt, grade 2 in 15 pts. Two pts experienced skin reaction grade 2. Response to treatment: Overall response rate was 61% (14/23 pts). The median follow-up was 6 months (from 2 to 21 months). Conclusion: This treatment schedule has an acceptable toxicity and notable response rate.
Descriptors		PLEURAL NEOPLASMS MESOTHELIOMA CISPLATIN ANTINEOPLASTIC AGENTS, COMBINED DISEASE-FREE SURVIVAL